Beck Jill C, Chen Baojiang, Gordon Bruce G
Jill C Beck, Baojiang Chen, Bruce G Gordon, Department of Pediatric Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198-2168, United States.
World J Clin Oncol. 2017 Aug 10;8(4):336-342. doi: 10.5306/wjco.v8.i4.336.
To evaluate personnel involved in scarce drug prioritization and distribution and the criteria used to inform drug distribution during times of shortage among pediatric hematologists/oncologists.
Using the American Society of Pediatric Hematology/Oncology (ASPHO) membership list, a 20 question survey of pediatric hematologists/oncologists was conducted email to evaluate personnel involved in scarce drug prioritization and distribution and criteria used to inform scarce drug distribution.
Nearly 65% of the 191 study respondents had patients directly affected by drug shortages. Most physicians find out about shortages from the pharmacist ( = 179, 98%) or other doctors ( = 75, 41%). One third of respondents do not know if there is a program or policy for handling drug shortages at their institution. The pharmacist was the most commonly cited decision maker for shortage drug distribution ( = 128, 70%), followed by physicians ( = 109, 60%). One fourth of respondents did not know who makes decisions about shortage drug distribution at their institution. The highest priority criterion among respondents was use of the shortage drug for curative, rather than palliative intent and lowest priority criterion was order of arrival or first-come first-served.
Despite pediatric hematology/oncology physicians and patients being heavily impacted by drug shortages, institutional processes for handling shortages are lacking. There is significant disparity between how decisions for distribution of shortage drugs are currently made and how study respondents felt those decisions should be made. An institution-based, and more importantly, a societal approach to drug shortages is necessary to reconcile these disparities.
评估参与稀缺药物优先级确定和分配的人员,以及儿科血液学家/肿瘤学家在药物短缺期间用于指导药物分配的标准。
利用美国儿科血液学/肿瘤学会(ASPHO)的会员名单,通过电子邮件对儿科血液学家/肿瘤学家进行了一项包含20个问题的调查,以评估参与稀缺药物优先级确定和分配的人员以及用于指导稀缺药物分配的标准。
191名研究受访者中近65%的人有患者直接受到药物短缺的影响。大多数医生从药剂师(n = 179,98%)或其他医生(n = 75,41%)那里得知药物短缺情况。三分之一的受访者不知道他们所在机构是否有处理药物短缺的计划或政策。药剂师是最常被提及的稀缺药物分配决策者(n = 128,70%),其次是医生(n = 109,60%)。四分之一的受访者不知道他们所在机构中谁负责做出稀缺药物分配的决策。受访者中最高优先级标准是将稀缺药物用于治疗目的而非姑息治疗目的,最低优先级标准是到货顺序或先到先得。
尽管儿科血液学/肿瘤学医生和患者受到药物短缺的严重影响,但处理短缺的机构流程仍不完善。目前稀缺药物分配决策的方式与研究受访者认为这些决策应如何做出之间存在显著差异。需要一种基于机构的,更重要的是基于社会的方法来解决这些差异,以应对药物短缺问题。